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Abstract.   This study describes the effect of  Naringenin on major histocompatibility complex (MHC) class I heavy chain gene
expression in the presence of  low risk or high risk Human Papillomavirus (HPV) E6 and E7 genes. Northern blot analysis
showed that, in the presence of  Naringenin, steady-state levels of  MHC class I heavy chain mRNA transcripts were elevated
in rat fibroblast (3Y1) cells. In transient expression assays of  MHC class I heavy chain (H-2Kb) promoter activity, it was
observed that there was a down-regulation of  MHC class I promoter activity in 3Y1 cells co-transfected with either high risk
HPV 16 E6 and E7 or low risk HPV 6 E6 and E7 expression plasmids. Treatment of  control 3Y1 cells and cells co-transfected
with high or low risk HPV E6 and E7 plasmids with 300µg/ml of  Naringenin for 24 hours led to an increase in H-2Kb-driven
CAT (chloramphenicol acetyl transferase) reporter gene activity. Thus, Naringenin retained the ability to increase H-2Kb
promoter activity in the presence of  either E6 or E7 expression constructs, indicating that Naringenin can over-ride the
transcriptional repressor effects of  HPV oncoproteins and may therefore have some potential immunostimulatory properties
in HPV-associated malignancy.
Keywords.   MHC Class I, papillomavirus, expression, naringenin
Abbreviations: MHC, Major Histocompatibility Complex; HPV, Human
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INTRODUCTION
Papillomaviruses are small DNA viruses associated with
benign and malignant proliferative lesions of  cutaneous
epithelium. HPV 6 and 11 are found in benign lesions such
as ano-genital condylomata acuminata and laryngeal
papilloma while HPV 16 and 18 are commonly associated
with cervical intraepithelial neoplasia (CIN), vaginal
intraepithelial neoplasia (VIN), penile intraepithelial
neoplasia (PIN), bowenoid papulosis and genital Bowen’s
disease, peri-anal and anal cancer (Howley and Lowy, 2001).
     The E6 and E7 genes of  genital HPVs interfere with
cellular tumour suppressor proteins whose normal function
is to regulate cell proliferation. Interactions of the E6 protein
with p53 and the E7 protein with the retinoblastoma
susceptibility gene product, p105 or pRb (Levine et al.,1991)
are found to be more stable in the high risk HPV types 16
or 18 (associated with malignant cancers) than in the low
risk HPV 6 or 11 derived from benign lesions (Werness et
al., 1990).
     Class I and class II molecules of the major
histocompatibility complex (MHC) play a key role in the
recognition of  foreign antigens by T cell receptors carried
by cytotoxic and helper T lymphocytes. The MHC class I
gene products are a highly polymorphic family of  cell surface
proteins responsible for presentation of  peptide antigens to
cytotoxic T cells (Fourie and Yang, 1998). Several studies
have examined the expression of  MHC class I and II
molecules in cervical lesions and any possible relationship
between the presence of  HPV and changes in MHC
expression. A significant proportion of  the tumours showed
down-regulation of  MHC class I molecules, which would
prevent effective cytotoxic T cell activity against potential
viral antigens (reviewed in Garrido and Algarra, 2001).
     As well as playing a key role in subverting the cell cycle,
the E7 gene products can repress multiple promoters in the
MHC class I antigen processing and presentation pathway
(Georgopoulus et al., 2000). This could lead to lowered levels
of  cell surface MHC class I molecules and thus the HPV-
transformed cells could evade cellular immune surveillance
mediated by CD8+ cytotoxic T lymphocytes (Eiben et al.,
2002).
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Flavonoids form a large class of  phenolic substances widely
distributed in nature (Di Carlo et al., 1993). Naringenin is
one of  the major naturally occurring flavones. Naringin
(4',5,7-trihydroxyflavanone 7-rhamno-glucoside), the so-
called ‘bitter principle’ of  grapefruit, is the most abundant
of these compounds and is usually present in concentrations
of  up to 800 mg/l of  juice (Rousseff  et al.,1987). Following
oral administration in humans, naringin is thought to be
converted to the aglycone, Naringenin. Naringenin exhibits
several biological effects such as anti-estrogenic activity, anti-
ulcer actions, inhibition of  human liver cytochrome P450
isoforms CYP 3A4, CYP 1A2 and other enzyme activities
as well as inhibition of  non-enzymatic lipid peroxidation
(Saija et al.,1995; Huang et al.,1997).
     Recognising the importance of  the control of  expression
of  MHC class I molecules in immune processes, in this study
attention was directed towards an understanding of  how
expression of  MHC class I heavy chain genes is regulated in
both normal cells and cells expressing HPV oncogenes and,
in particular, in any possible effects of  Naringenin on MHC
class I heavy chain gene expression. Since Naringenin is
known to have multiple biological effects (such as anti-
estrogenic and ulcer protecting effects), it was of  interest to
test its potential immunostimulatory and anti-viral effects,
particularly on the expression of  a key cellular MHC gene
in the presence of  the HPV 6 or 16 E6 and E7 genes. In this
study we have shown that HPV E6 and E7 down-regulated
MHC class I heavy chain gene expression and that
Naringenin has the ability to overcome this repressive effect
of  HPV oncoproteins.
MATERIALS AND METHODS
Cell culture.   The 3Y1 cell line which is a rat fibroblast
(Kimura et al., 1975), was grown in RPMI supplemented
with 10% foetal calf  serum, penicillin and streptomycin
(hereafter termed “complete medium”) and maintained in a
humidified atmosphere of  95% air, 5% CO
2
. Cells were
detached with trypsin-EDTA and seeded in 60mm dishes
for experimental analysis. All cell culture media and materials
were obtained from Gibco-BRL, U.K. Naringenin was
obtained from the Sigma Chemical Company Ltd., USA.
The required amount of  Naringenin was dissolved in 100%
ethanol and added to cell cultures at a concentration of
300µg/ml.
Transient expression assay.   The plasmid H2K-CAT
contains 2 kb of  5′ flanking region of  the H-2Kb class I
gene cloned in the multiple cloning site of  pBLCAT 3
(Proffitt et al., 1996). The E6 or E7 open reading frames of
HPV 6b or 16 were previously cloned into pUC 19 under
the control of  the Moloney murine leukaemia virus
transcriptional regulatory elements (Barbosa et al., 1991).
Prior to transfection, cells were plated at an appropriate
density and grown for 24 hours to a confluency of  60% in
60 mm dishes. After 24 hours of  incubation, the cells were
transfected by the calcium phosphate method using a
commercial kit (Pharmacia Biotech., U.S.A.) with either 15µg
of  H2K-CAT reporter gene plasmid and/or 15µg of  the
HPV 6b or 16 E6 or E7 expression plasmid. The cells were
incubated with the calcium phosphate-DNA precipitate at
37°C in a humidified atmosphere containing 5% CO
2
 for 6
hours. After 6 hours, the precipitate was removed, the cells
were washed three times with RPMI medium and 3 ml of
complete medium was added for the subsequent incubation
at 37°C in a CO
2
 incubator and treated with 100% ethanol
as control and either 300µg/ml or 757.5µg/ml Naringenin .
Twenty four hours later, the cells were processed for RNA
analysis or assayed for chloramphenicol acetyltransferase
(CAT), using a CAT ELISA Kit (Boehringer Mannheim,
Germany).
Chloramphenicol Acetyl transferase (CAT) assay.
Microtiter plate modules were used. Two hundred microliters
of  CAT standard working dilution or 200µl of  cell extract
was pipetted per well. The microtiter plate was incubated
for one hour at 37oC. The solution was removed and the
wells were rinsed with 250µl of  phosphate buffer saline for
30 seconds. The washing buffer was removed and 200µl of
anti-CAT-digoxigenin was added and incubated for one hour.
The solution was then removed and rinsed with PBS. The
washing buffer was removed and 200µl of  anti-digoxigenin-
POD was added and incubated for another hour. The
solution was removed and 200µl of  POD substrate was
added until colour development was sufficient for
photometric detection at 405 nm. The CAT activity was
expressed as CAT concentration (ng/ml). The results were
obtained from the average of  three experiments. The fold-
induction ratios of  CAT activity were calculated by dividing
the CAT activity from extracts of  cells treated with
Naringenin or 100% ethanol by that of  the untreated, H2K-
CAT-transfected cells.
mRNA analysis.   Total RNA isolation was performed using
TRIZOL (Gibco-BRL, U.K.) and analysed by Northern
blotting using standard methods (Sambrook et al., 1989).
DNA probes were either a 1.8 kb Pst I fragment of  the
murine H-2Kb gene (Ackrill and Blair, 1988) or a plasmid
pAL41 containing a partial cDNA clone of  mouse B-actin
(Minty et al.,1983). Labelling was performed by nick
translation (Sambrook et al., 1989) using [α-32P]dCTP
(Amersham International plc, U.K.). The specific activity of
the labeled probes was approximately 108  dpm/µg.
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RESULTS
Steady-state levels of  MHC class I heavy chain mRNAs
in 3Y1 cells treated with Naringenin.   Since the main
aim of  this investigation was to screen for any
immunostimulatory or anti-viral effects produced by
Naringenin, it was therefore of  interest to investigate whether
elevated levels of  MHC class I transcripts could be detected
in Naringenin-treated 3Y1 fibroblasts. 3Y1 cells were chosen
for this analysis since previous studies had shown that both
endogenous MHC class I gene expression and transfected
class I promoters could be modulated by adenovirus E1A
oncoproteins (13). 3Y1 cells were treated with 300 µg/ml
of  Naringenin for 24 hours. Analysis of  total cellular RNA
samples by formaldehyde-agarose gel electrophoresis
confirmed that intact total RNA had been isolated from cells
and two predominant species (of  4.98 kb and 1.91 kb,
corresponding to 28S and 18S ribosomal RNAs) could be
detected at equal level in both control and Narigenin-treated
cells (Figure 1A). Northern blot hybridisation using the nick-
translated class I DNA probe showed a modest but
reproducible increase in MHC class I transcript levels after
24 hours of  Naringenin treatment (Figure 1B). Control
hybridisation using nick-translated β-actin cDNA showed
that the β-actin mRNA level in Naringenin treated and
control 3Y1 cells was only slightly affected by Naringenin
treatment. Densitometric analysis of  autoradiographs
showed that the class I/β-actin ratio increased by
approximately 1.4 fold upon Naringenin treatment of  3Y1
cells. This suggested that there could be an increase in
transcription of  class I genes in Naringenin-treated 3Y1 cells.
This directed our attention towards analysing the activity of
an MHC class I promoter linked to a CAT reporter gene in
control and Naringenin-treated cells.
The effect of  naringenin on the MHC class I promoter
activity.   Experiments were therefore performed to
investigate the effects of  different concentrations of
Naringenin on the MHC class I promoter activity using
transient expression assays in 3Y1 cells. When 3Y1 cells were
transfected with a plasmid in which 2 kb of  5' flanking region
of  the mouse H-2Kb class I heavy chain gene was linked to
a CAT reporter gene (H2K-CAT) and treated with 100%
ethanol as control and either 300µg/ml or 757.5µg/ml
Naringenin (Fig. 2), it could be seen that there was a
stimulation of  H-2Kb promoter activity at the lower
concentration of  Naringenin (300µg/ml), giving a two-fold
increase in CAT activity after 24 hrs of  treatment. However
Figure 1.   Steady-state levels of  MHC class I heavy chain mRNAs in 3Y1 cells treated with Naringenin.
A. Ethidium bromide-stained formaldehyde 1%(w/v) agarose gel showing the integrity of  total RNA isolated from Naringenin-treated
and control 3Y1 cells.  The cells were treated with 300 µg/ml of  Naringenin for 24 hr. Total RNA was isolated. Lane 1: mRNA isolated
from control 3Y1 cells. Lane 2: mRNA isolated from Naringenin-treated 3Y1 cells
B. Northern blot analysis of  levels of  mRNA expressed in Naringenin-treated and control 3Y1 cells. Total RNA was isolated from each
culture and aliquots (10 µg) of  RNA analysed by Northern blotting and hybridization with either a nick-translated H-2Kb insert (panel
a) or β-actin insert (panel b). Lane 1: mRNA isolated from control 3Y1 cells. Lane 2: mRNA isolated from Naringenin-treated 3Y1 cells.
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at the higher concentration of  Naringenin (757.5 µg/ml),
H-2Kb promoter activity appeared to be down-regulated.
Therefore standard conditions for Naringenin treatment
were adopted, typically 24 hrs of  treatment with 300 µg/ml
of  Naringenin. Interestingly it was also observed that high
concentrations of  Naringenin (700 µg/ml) seemed to be
toxic to the cells.
The effect of  HPV 6b and 16 E6 and E7 oncoproteins
on MHC class I promoter activity.   To ascertain the effect
of the E6 and E7 oncoproteins on MHC class I promoter
activity, co-transfection of  3Y1 cells was performed with
equivalent (10 µg) masses of  either control pUC19, HPV
6b E6, HPV 16 E6, HPV 6b E7 or HPV 16 E7 expression
plasmid and 15 µg of  H2K-CAT plasmid DNA. When the
pUC19 and H2K-CAT plasmids were co-transfected into
3Y1 cells, it was observed that there was no significant
reduction of  CAT expression, which shows that the cells
are unaffected by the pUC19 plasmid. On the other hand,
in cells co-transfected with pUC19, H2K-CAT and either
the HPV6b or 16 E6 or E7 plasmids, CAT expression was
significantly reduced. The CAT expression level was
suppressed to about 0.48-fold for HPV 6 E6 co-transfected
cells, 0.38-fold for HPV 16 E6 co-transfected cells, 0.29-
fold for HPV 6 E7 co-transfected cells and 0.42-fold for
HPV 16 E7 co-transfected cells (Fig. 3). This therefore
implied that the down-regulation in MHC class I heavy chain
gene expression could be directly related to the presence of
the E6 and E7 gene products, with the resulting CAT activity
being repressed the most in the presence of  the HPV 6 E7
gene product.
The effect of  Naringenin on MHC class I promoter
activity in cells expressing the HPV E6 and E7
oncoproteins.   Experiments were performed to determine
the effect of  Naringenin in cells expressing the HPV  E6 or
E7 gene products (Fig. 2). Co-transfections of  10 µg masses
of either pUC19, HPV 6 E6, HPV 16 E6, HPV 6 E7 or
HPV 16 E7 plasmid and 15 µg of  H2K-CAT plasmid into
the 3Y1 cells were performed and then treated with
Naringenin for 24 hrs. When 3Y1 cells were co-transfected
with pUC19 and H2K-CAT followed by treatment with
Naringenin for 24 hrs, an increase in CAT activity was
observed and the CAT induction level was about 2-fold,
again showing that CAT expression driven by H2K-CAT
was again increased in the presence of  Naringenin. In
addition, in all co-transfected cells, an increase in CAT activity
over the basal levels was observed in the presence of
Naringenin. The CAT induction level was about 25-fold for
the HPV 6 E6 co-transfection, 6.7-fold for the HPV 16 E6
co-transfection, 35-fold for the HPV 6 E7 co-transfection
and 3.6-fold for HPV 16 E7 co-transfection (Fig. 4). Thus,
3Y1 cells co-transfected with HPV 6 E7 or HPV 6 E6
exhibited much higher CAT activities compared to the same
cells with HPV 16 E6 or HPV 16 E7. In summary, it was
therefore established that Naringenin could overcome the
effect of  HPV 6 or 16 E6 and E7 gene products on MHC
class I expression.
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Figure 2.   The effect of  different concentrations of  Naringenin
on MHC class I heavy chain promoter activity in 3Y1 cells.
 The cells were treated for 24 hr with 100% ethanol as a control
and either 300µg/ml or 757.5 µg/ml Naringenin and the CAT assay
was performed. The CAT activity was expressed as
CAT concentration (ng/ml). The results were obtained from the
average of  three experiments. The fold-induction ratios of
CAT activity were calculated by dividing the CAT activity from
extracts of  cells treated with Naringenin or 100% ethanol by that
of  the untreated, H2K-CAT-transfected cells.
Figure 3.   The effect of  co-transfection of  HPV E6 or E7-
expression plasmids on MHC class I heavy chain promoter activity
in 3Y1 cells. The H2K-CAT plasmid was co-transfected with either
the control plasmid (pUC19) or HPV 6 E6, HPV 6 E7, HPV 16
E6, HPV 16 E7 expression plasmid.
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Figure 4.   The effect of  Naringenin on MHC class I promoter
activity in 3Y1 cells expressing HPV E6 or E7 gene products.
The H2K-CAT plasmid was co-transfected with either the control
plasmid (pUC19) or HPV 6 E6, HPV 6 E7, HPV 16 E6,
 HPV 16 E7 plasmids and was treated for 24hrs with 300µg/ml
naringenin
DISCUSSION
Northern blot results obtained with the Naringenin-treated
and control 3Y1 cells showed that there is an elevated level
of  MHC class I heavy chain transcripts in Naringenin-treated
3Y1 cells. This suggested that the class I mRNA transcription
might be increased in Naringenin-treated 3Y1 cells, leading
to the observed elevated levels of  class I heavy chain mRNA.
This directed our attention towards analyzing transcription
of  class I genes in transfected cells by studying an MHC
class I promoter (derived from the mouse H-2Kb gene) linked
to a CAT reporter gene.
     The expression of  MHC class I genes was known to be
reduced in HPV 16-associated tumours and it has been
proposed that this allows HPV 16-transformed cells to
escape immune surveillance and to form tumours in the
human host (Cromme et al., 1993). The results presented
here demonstrate that HPV 16 E6 and E7 and HPV 6 E6
and E7 gene products have the ability to down-regulate the
MHC class I promoter in co-transfection experiments in
3Y1 cells. This suggests that the E7 gene and E6 gene of
both the low- and high-risk HPV genotypes may play a role
in the repression of  MHC class I antigen processing and
presentation pathway. The ability of  Naringenin to restore
the activity of  the class I heavy chain promoter indicates
that the cells are not deficient in MHC class I expression
(for example, by mutations or rearrangements in class I
genes) but rather that E6 and E7 are actively repressing class
I transcription and that Naringenin can overcome these
repressory effects.
     The mechanism(s) responsible for the repression of  class
I heavy chain promoters and their up-regulation by
Naringenin remain to be elucidated.  One possibility is that
the level or activity of  transcription factors that are common
to multiple class I antigen processing and presentation genes
might be modulated by HPV oncoproteins and Naringenin.
Such a well-characterised candidate transcription factor is
NF-κB, whose activity is regulated by phosphorylation and
binding of  inhibitory proteins (Ghosh and Baltimore, 1990;
Liou et al., 1992). Future work will focus on studies of  DNA
binding and activity of  this and other transcription factors
involved in regulating expression of  MHC genes in HPV-
transformed and Naringenin-treated cells.
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